SIGNIFICANTLY IMPROVED OVERALL RESPONSE RATE WITH RUXOLITINIB IN GLUCOCORTICOID-REFRACTORY GRAFT-VERSUS-HOST DISEASE
The REACH3 phase III randomised trial evaluated ruxolitinib as compared with investigator’s choice of therapy from a list of ten commonly used options among patients with glucocorticoid-refractory or –dependent chronic graft-versus-host disease. Primary analysis demonstrates a significantly greater overall response, failure-free survival, and symptom response…
SIGNIFICANTLY HIGHER COMPLETE HAEMATOLOGICAL RESPONSE WITH DARATUMUMAB IN SYSTEMIC IMMUNOGLOBULIN LIGHT-CHAIN AMYLOIDOSIS
The phase III ANDROMEDA study evaluates the safety and efficacy of subcutaneous daratumumab plus bortezomib, cyclophosphamide and dexamethasone in patients with newly diagnosed light-chain (AL) amyloidosis. Primary results from the randomised portion of the trial demonstrates higher frequencies of haematologic complete response and survival free from major organ deterioration or haematologic progression…
LONG-TERM TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA AFTER SECOND-LINE NILOTINIB
The ENESTop study evaluated treatment-free remission (TFR) in patients with chronic myeloid leukaemia (CML) in chronic phase who had received ≥3 years of tyrosine kinase inhibitor therapy and achieved sustained deep molecular response only after switching from imatinib to nilotinib. Results from a five-year update further confirm the durability and safety of TFR for patients receiving second-line nilotinib…
BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY IMPROVES PFS COMPARED TO STANDARD OF CARE IN STAGE III/IV HODGKIN’S LYMPHOMA
The primary analysis of the phase III ECHELON-1 study, comparing brentuximab vedotin, doxorubicin, vinblastine and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) in patients with stage III/IV classical Hodgkin’s lymphoma, previously reported an improvement in progression-free survival (PFS) with A+AVD. At five years, A+AVD continues to show robust and durable improvement in PFS versus ABVD, regardless of PET-2 status...
SUPERIOR SURVIVAL WITH PAEDIATRIC-STYLE CHEMOTHERAPY FOR AYA’S WITH PH-NEGATIVE ALL IN FIRST COMPLETE REMISSION
For adolescents and young adults (AYA’S) with Philadelphia-negative acute lymphoblastic leukaemia in first complete remission, the optimal post-remission therapy remains unknown. However, an analysis from CALGB 10403 and the CIBMTR now demonstrates that post-remission therapy with paediatric-style chemotherapy is superior to myeloablative allogeneic haematopoietic stem cell transplantation for overall survival, disease-free survival and non-relapse mortality…
Top
